In the clinical trials of the SUSTAIN program, OW s.c. semaglutide consistently demonstrated superior glycemic control and weight loss versus either other anti-hyperglycemic agents or other GLP-1 RAs, in a variety of T2D patient cohorts [reviewed in (11)]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.